Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FTY720 for Acute Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke~* MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke~* Time to fty720 treatment\< 72 h from symptom onset~* Glasgow Coma Score \>6 on initial presentation or improvement to a Glasgow Coma Score \>6 within the time frame for enrollment.~* Primary supratentorial ICH of ≥5cc and \<30cc~* TOAST: Large-artery atherosclerosis~Exclusion Criteria:~* Patients who will undergo surgical evacuation of intracerebral hemorrhage~* Inability to undergo neuroimaging with Magnetic Resonance~* Glasgow Coma Score \< 6.~* Baseline modified Rankin Scale score \>1~* Primary intraventricular hemorrhage ICH due to coagulopathy (PT \> 15 s or International Normalized Ratio \> 1.3, Partial Thromboplastin Time \> 36) or trauma~* Thrombocytopenia: platelet count \<100 000~* Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs \>2x normal, coagulopathy as described)~* Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome~* Pregnancy~* Malignancy (history of or active)~* Bradyarrhythmia and Atrioventricular Block~* Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies~* Macular Edema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (FTY720) group (Type: EXPERIMENTAL): Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
- Control group (Type: PLACEBO_COMPARATOR): Patients will receive usual care and drug use in hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).